As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Featured Article: Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?
In this review article, the authors discuss the potential for extracellular HMGB1 as a target for treating COVID-19.
Announcement: COVID-19 impact on peer review
Aims and scope
Molecular Medicine is an open access journal publishing recent findings that elucidate disease pathogenesis at the molecular or physiological level, which may lead to the design of specific tools for disease diagnosis, treatment, or prevention. Manuscripts containing material relevant to the genetic, molecular, or cellular basis of key physiologic or disease processes are considered for publication. Manuscripts submitted to Molecular Medicine should describe the implications of the results for human disease and medicine, at a level approachable by our broad audience.
Nobel congratulations to William G. Kaelin Jr
Molecular Medicine is happy to congratulate William G. Kaelin Jr on being a winner of The Nobel Prize in Physiology or Medicine 2019. Professor Kaelin Jr was chosen for his work on the discoveries of how cells sense and adapt to oxygen availability. He previously contributed an article to our journal, "The Molecular Basis of Von Hippel-Lindau Disease", which you can read here.
Articles
-
-
Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
-
Combination of TLR agonist and miR146a mimics attenuates ovalbumin-induced asthma
-
The cholinergic anti-inflammatory pathway alleviates acute lung injury
-
The α7 nicotinic acetylcholine receptor agonist, GTS-21, attenuates hyperoxia-induced acute inflammatory lung injury by alleviating the accumulation of HMGB1 in the airways and the circulation
-
Erythropoiesis: insights into pathophysiology and treatments in 2017
-
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
-
Serum amyloid A – a review
-
The cholinergic anti-inflammatory pathway in resistant hypertension treated with renal denervation
-
SRC-2 Coactivator: a role in human metabolic evolution and disease
Featured cross-journal series: Molecular mechanisms and therapeutic relevance of neuro-immune communication
Our new cross-journal thematic series (published in conjunction with Bioelectronic Medicine), calls for submissions focusing on the molecular mechanisms and therapeutic exploration at the interface between the immune and nervous systems in health and disease and the therapeutic exploration of this insight. It will also cover emerging areas such as the neuronal regulation of hematopoiesis and innate and adaptive immunity. The series is guest edited by Sangeeta Chavan, Colin Reardon, and Niccolò Terrando. Find more information here.
Announcing our new article types
Our journal is proud to offer four new article types, ready for submissions!
- Mini-reviews, which provide a concise summary of a specific research topic or field relevant to our scope
- Perspectives, which grants the opportunity to write about the current state and recent developments of a research field or topic within our scope and point to associated challenges and future directions
- Opinions, written with a specific focus on a previously published article which has had a major impact on the field.
- Commentaries, invited pieces which provide further discussion on a primary research manuscript.
Please see our Submission Guidelines page for more.
Reviewers of the quarter
Molecular Medicine would like to recognize the efforts of the exceptional peer reviewers, for their excellent service. This individual has exceeded expectations as far as acceptance rate, the number of completed reviews, and timeliness, during the fourth quarter of 2019. The journal cannot succeed without its peer reviewers, and we thank the hard-working members of our network.
Monowar Aziz
About the Editors
Dr Betty Diamond (Editor-in-Chief) graduated with a BA from Harvard University and an MD from Harvard Medical School. She performed a residency in Internal Medicine at Columbia Presbyterian Medical Center and received postdoctoral training in immunology at the Albert Einstein College of Medicine.
Dr Diamond has headed the Rheumatology Divisions at Albert Einstein School of Medicine and at Columbia University Medical Center. She also directed the Medical Scientist Training Program at Albert Einstein School of Medicine for many years. She is currently head of the Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases at The Feinstein Institutes for Medical Research and Director of the PhD and MD/PhD programs at the Zucker School of Medicine at Hofstra-Northwell.
A past president of the American Association of Immunology, Dr Diamond has also served on the Board of Directors of the American College of Rheumatology and the Scientific Council of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Dr Diamond is a Fellow of the American Association for the Advancement of Science (AAAS) and a member of the National Academy of Medicine.
Valentin Pavlov, The Feinstein Institutes for Medical Research, USA- Executive Editor
Maria Ruggieri, The Feinstein Institutes for Medical Research, USA- Managing Editor
Sonya VanPatten, The Feinstein Institutes for Medical Research, USA- Coordinating Editor
Awards
Anthony Cerami Award in Translational Medicine
Molecular Medicine has established the Anthony Cerami Award in Translational Medicine to honor investigators who have created the fundamental innovation necessary for molecular medicine to advance into clinical practice. The award recognizes leading edge discoveries that have led to improvement of human health, and have opened the door to new therapeutic advances and understanding. Find out more.
Ross Prize in Molecular Medicine
The annual Ross Prize in Molecular Medicine is established in conjunction with the Feinstein Institutes for Medical Research and Molecular Medicine. The winner will be an active investigator having produced innovative, paradigm-shifting research that is worthy of significant and broad attention in the field of molecular medicine. Find out more.
Message from the Editors
What happens when the immune system goes rogue?
In her 2017 TEDMED Talk, Editor-in-Chief Dr Betty Diamond discusses the latest insights in autoimmune disease research, and the pivotal role that patients play in studies.
Pre-submission inquiries
The Editors of Molecular Medicine welcome authors to send any pre-submission inquiries they might have, here. We ask that you please include “Pre-submission inquiry” in the subject line of your email and that you include the title and abstract of your proposed submission within the message. Our Editors will do their best to respond to you in a timely manner.
Bioelectronic Medicine
If you enjoy Molecular Medicine, we invite you to visit Feinstein’s Bioelectronic Medicine (published by BMC). Bioelectronic Medicine focuses on the regulatory functions of the nervous system and technologies that record, stimulate, or block neural signaling to affect specific molecular mechanisms in health and disease. It also features bioelectronic approaches for monitoring and controlling biological processes and for providing insights into disease pathogenesis that can be utilized in new treatments of inflammatory, neurodegenerative, gastrointestinal, and cardiovascular diseases, paralysis, and many other conditions.
About Feinstein Institutes for Medical Research
Molecular Medicine is published in partnership with The Feinstein Institutes for Medical Research. As the research arm of Northwell Health, the largest healthcare provider in New York, it is home to 50 research laboratories and to clinical research throughout dozens of hospitals and outpatient facilities. The Feinstein Institutes include 4,000 researchers and staff who are making breakthroughs in molecular medicine, genetics, oncology, brain research, mental health, autoimmunity, and bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how the Feinstein Institutes empower imagination and pioneers discovery, visit FeinsteinInstitute.org.
Annual Journal Metrics
-
Speed
46 days to first decision for reviewed manuscripts only
28 days to first decision for all manuscripts
118 days from submission to acceptance
25 days from acceptance to publication
Citation Impact
2.991 - 2-year Impact Factor
4.039 - 5-year Impact Factor
0.923 - Source Normalized Impact per Paper (SNIP)
1.403 - SCImago Journal Rank (SJR)
Usage
323,522 downloads
224 Altmetric mentions
